Correcting for cell-type heterogeneity in DNA methylation: a comprehensive evaluation
Rahmani et al. reply: Zheng et al. 1 discuss potential pitfalls in our evaluation of ReFACTor 2 , a reference-free method to account for cell-type heterogeneity. Below, we reproduce their analysis and demonstrate that conclusions cannot be drawn on the basis of their results owing to conceptual and technical flaws in their analysis. We show with our reanalysis and further evidence from experiments on a total of 10 data sets that ReFACTor has improved performance over alternative methods, including the referencebased method of Houseman et al. 3 .
Zheng et al. 1 claim that more evidence needs to be provided to determine whether ReFACTor is applicable to tissues other than blood. They generated a "gold standard" set of "true positives" and "true negatives" for breast cancer differentially methylated CpGs (DMCs) and compared ReFACTor to Surrogate Variable Analysis (SVA) 4 using EWAS data. There are multiple problems with this analysis. First, the list of 'true positives' is unreliable owing to the fact that only two control individuals were used for its construction (Supplementary Note 1). We show through a simple permutation analysis that using only two controls is likely to result in tens of thousands of spurious 'true positives' ( Supplementary  Fig. 1 ). Therefore, benchmarking on these 'true positives' is an invalid approach. Second, Zheng et al. 1 report improved sensitivity for SVA; however, they do not report that a simple unadjusted analysis using a standard Bonferroni significance level achieves considerably better sensitivity and greater specificity than SVA (Supplementary Table 1 ). Thus, the metric used to evaluate performance is also invalid, as the naive method that does not adjust for cell-type heterogeneity outperforms a method that does. A detailed description of this experiment as well as additional flaws in their analysis is given in Supplementary Note 1.
The focus of Zheng et al. 1 on the potential loss of power in the case of many true positives is of interest. Because a reliable gold standard is currently not available, we examined this scenario by splitting a large set of breast cancer samples (n = 305) 5 into two groups on the basis of the reference-based cell-composition estimates provided by Zheng et al. 1 . One group was labeled as controls, and differential methylation effects were added to all samples in the other group in more than 20,000 sites. Note 3) . They evaluated ReFACTor by measuring the correlation between each cell type and ReFACTor components selected via likelihood ratio test (LRT) and observed that ReFACTor only slightly improves upon the reference-based approach. However, LRT depends on sample size, hence we re-evaluated ReFACTor using LRT with all 560 samples in the data set (as opposed to a subset). Our analysis revealed more significant components, which leads to a substantial improvement, far outperforming the reference-based approach (Supplementary Note 3 and Supplementary Fig. 3) .
Finally, Zheng et al. 1 try to demonstrate the advantage of the reference-based method 3 using a very small data set with known cell composition (n = 18) 6 . However, in their analysis, Zheng et al. 1 Fig.  4) . Furthermore, such a small sample size cannot provide statistically significant evidence for the improvement of any method. Specifically, using multiple subsampled FACS data sets of 18 samples, we observed that the performance of both methods was highly variable (Supplementary Fig. 5 ). Moreover, Zheng et al. 1 relied on a method for determining the dimension of the data (RMT) 7 . We found that the number of dimensions estimated by RMT is linearly determined by the sample size (R 2 > 0.95), making it inapplicable ( Supplementary Fig. 6 and Supplementary Note 3) .
did not correct for known batch effects, and we found that adjusting for batch information produces similar performance for ReFACTor and the reference-based method (Supplementary
Given that firm conclusions cannot be drawn based on small data sets, we further evaluated the performance of ReFACTor and the reference-based method using five large whole-blood data sets (minimum n = 312). We divided the samples in each data set into two groups on the basis of cell-composition distribution (Supplementary Note 3) . Then, we conducted an EWAS on the assignment into groups as the phenotype. In this scenario, the assignment into groups is expected to be correlated with the true underlying cell composition, and an insufficient correction will lead to spurious associations. We found that ReFACTor consistently outperformed the reference-based method; particularly, the 
